We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
RSS Email Alerts
Please Wait... Processing your request... Please Wait.

Journal Articles

in Pharmacogenetics/Pharmacogenomics

Sign in

Purchase Options

• Subscribe to the journal
• Rent this article ?

A free personal account provides

• Free current issues on The JAMA Network Reader
• Free quizzes on The JAMA Network Challenge
• Commenting and personalized alerts
From The JAMA Network
JAMA Oncology
Editorial  | 
Trastuzumab and Cardiac Outcomes in Breast Cancer A Story We Know by Heart?
Gérard Milano, PhD; Emmanuel Chamorey, PharmD, PhD; Jean-Marc Ferrero, MD, PhD
JAMA Oncology
Editorial  | 
Oral Cancer Chemoprevention—The End of EPOC, the Beginning of an Epoch of Molecular Selection
Julie E. Bauman, MD, MPH; Jennifer Grandis, MD
JAMA Oncology
Original Investigation  | 
Cardiac Outcomes of Patients Receiving Adjuvant Weekly Paclitaxel and Trastuzumab for Node-Negative, ERBB2-Positive Breast Cancer
Chau Dang, MD; Hao Guo, MS; Julie Najita, PhD; et al.
JAMA Oncology
Original Investigation  | 
Erlotinib and the Risk of Oral Cancer The Erlotinib Prevention of Oral Cancer (EPOC) Randomized Clinical Trial
William N. William Jr, MD; Vassiliki Papadimitrakopoulou, MD; J. Jack Lee, PhD; et al.